People · Operator
Named in public records as an officer, director or promoter · active 2018–2021 · Other, Pharma, Healthtech, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ORIG3N, Inc. | — | Other | Series B | $32.8M | $434.9M | 2018 |
| Endogena Therapeutics, Inc. | — | Pharma | Series A | $15.3M | $124.6M | 2020 |
| Abilitech Medical, Inc. | — | Healthtech | Series A | $12.7M | $42.5M | 2018 |
| BioEclipse Therapeutics, Inc. | — | Biotechnology | Series A | $10.1M | $366.1M | 2019 |
| Aegle Therapeutics Corp | — | Biotechnology | Series A | $7.0M | $1.2M | 2020 |
Elona Baum at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Elona Baum on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Clay Thorp | 1 | 10 |
| Byron Smith | 1 | 8 |
| Robert Ryan | 1 | 8 |
| Steve O'Hara | 1 | 6 |
| Biao He | 1 | 5 |
| Aaron Fletcher | 1 | 5 |
| Donald Santel | 1 | 4 |
| Stephen Thau | 1 | 4 |
| Robin Smith | 1 | 4 |
| Catherine Sohn | 1 | 3 |
| Mark Frohlich | 1 | 3 |
| Aaron Weaver | 1 | 3 |
| Leon Moulder, Jr. | 1 | 3 |
| Leon Moulder | 1 | 3 |
| Robin Y. Smith | 1 | 2 |
| Justin Xiang | 1 | 2 |
| Scott Braunstein | 1 | 2 |
| Dirk Harbecke | 1 | 2 |
| David Schimel | 1 | 2 |
| Angie Franks | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.